Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | FNTA | P49354 | 4/20 | 0.32 |
| ▸ | FNTB | P49356 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978270 | 0.84 | TLR7 (0.54) | TLR7TLR9MEN1KMT2AHRH1 | |
| SCHEMBL4980317 | 0.81 | TLR7 (0.48) | TLR7TLR9MEN1KMT2AHRH1 | |
| SCHEMBL4975436 | 0.79 | LMNA (0.41) | LMNA | |
| SCHEMBL4979798 | 0.79 | TLR7 (0.38) | TLR7TLR9MEN1KMT2AHRH1 | |
| SCHEMBL4977027 | 0.79 | TLR7 (0.52) | TLR7TLR9MEN1KMT2AHRH1 | |
| SCHEMBL4978177 | 0.78 | TLR7 (0.51) | TLR7TLR9MEN1KMT2AHRH1 | |
| SCHEMBL4979734 | 0.78 | TLR7 (0.51) | TLR7TLR9MEN1KMT2AHRH1 | |
| SCHEMBL4981943 | 0.77 | MEN1 (0.55) | TLR7MEN1KMT2AHRH1HRH3 | |
| SCHEMBL4975375 | 0.77 | TLR7 (0.40) | TLR7TLR9MEN1KMT2AHRH1 | |
| SCHEMBL4978082 | 0.77 | TLR7 (0.43) | TLR7TLR9MEN1KMT2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | TLR7 799/4885TLR9 653/4885MEN1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.